PT2079456E - Composições farmacêuticas de ciclosporina - Google Patents

Composições farmacêuticas de ciclosporina

Info

Publication number
PT2079456E
PT2079456E PT87198966T PT08719896T PT2079456E PT 2079456 E PT2079456 E PT 2079456E PT 87198966 T PT87198966 T PT 87198966T PT 08719896 T PT08719896 T PT 08719896T PT 2079456 E PT2079456 E PT 2079456E
Authority
PT
Portugal
Prior art keywords
minicapsules
liquid
cyclosporin compositions
pharmaceutical
therapeutic
Prior art date
Application number
PT87198966T
Other languages
English (en)
Portuguese (pt)
Inventor
Ivan Coulter
Original Assignee
Sigmoid Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigmoid Pharma Ltd filed Critical Sigmoid Pharma Ltd
Publication of PT2079456E publication Critical patent/PT2079456E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A61K9/5057—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
PT87198966T 2007-04-04 2008-04-04 Composições farmacêuticas de ciclosporina PT2079456E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90749007P 2007-04-04 2007-04-04
US649808P 2008-01-16 2008-01-16

Publications (1)

Publication Number Publication Date
PT2079456E true PT2079456E (pt) 2013-03-13

Family

ID=39745242

Family Applications (1)

Application Number Title Priority Date Filing Date
PT87198966T PT2079456E (pt) 2007-04-04 2008-04-04 Composições farmacêuticas de ciclosporina

Country Status (11)

Country Link
US (11) US8535713B2 (cg-RX-API-DMAC7.html)
EP (5) EP2061440A2 (cg-RX-API-DMAC7.html)
JP (6) JP2010523555A (cg-RX-API-DMAC7.html)
CN (6) CN101686948B (cg-RX-API-DMAC7.html)
CA (3) CA2683415C (cg-RX-API-DMAC7.html)
CY (1) CY1113882T1 (cg-RX-API-DMAC7.html)
DK (1) DK2079456T3 (cg-RX-API-DMAC7.html)
ES (3) ES2400964T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20130173T1 (cg-RX-API-DMAC7.html)
PT (1) PT2079456E (cg-RX-API-DMAC7.html)
WO (3) WO2008122966A2 (cg-RX-API-DMAC7.html)

Families Citing this family (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2922402B2 (ja) 1993-10-14 1999-07-26 住友重機械工業株式会社 熱成形方法及びその熱成形装置
JP2010523555A (ja) 2007-04-04 2010-07-15 シグモイド・ファーマ・リミテッド 「経口医薬組成物」
EP2061587A1 (en) 2007-04-26 2009-05-27 Sigmoid Pharma Limited Manufacture of multiple minicapsules
CA2685591A1 (en) * 2007-05-01 2008-11-06 Sigmoid Pharma Limited Pharmaceutical nimodipine compositions
AU2009225434B2 (en) 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
NZ592673A (en) 2008-11-13 2013-01-25 Giuliani Int Ltd Antisense compositions with enteric coating for treating crohn's disease, colitis and bowel disease
ES2530049T3 (es) 2009-05-18 2015-02-26 Sigmoid Pharma Limited Composición que comprende gotas de aceite
BR112012002963A2 (pt) * 2009-08-12 2017-10-24 Sigmoid Pharma Ltd composições imunomoduladoras compreendendo uma matriz de polímero e uma fase oleosa
US20170079962A1 (en) 2009-11-11 2017-03-23 Rapamycin Holdings, Llc Oral Rapamycin Preparation and Use for Stomatitus
US10391059B2 (en) 2009-11-11 2019-08-27 Rapamycin Holdings, Inc. Oral rapamycin nanoparticle preparations and use
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
KR101245078B1 (ko) * 2010-11-11 2013-03-18 부산대학교 산학협력단 대장 선택성 셀레콕시브 전구체 화합물 및 이를 유효성분으로 함유하는 대장성 질환 치료 또는 예방용 약학조성물
GB201020032D0 (en) * 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
EP4316488A3 (en) 2011-03-23 2024-02-28 Ironshore Pharmaceuticals & Development, Inc. Methods and compositions for treatment of attention deficit disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
WO2012145749A1 (en) 2011-04-22 2012-10-26 Napo Pharmaceuticals, Inc. Pharmacologically optimized multimodal drug delivery system for nordihydroguiaretic acid (ndga)
CN118078979A (zh) * 2011-04-29 2024-05-28 西莱克塔生物科技公司 用于降低针对治疗性蛋白的免疫应答的致耐受性合成纳米载体
US9561241B1 (en) * 2011-06-28 2017-02-07 Medicis Pharmaceutical Corporation Gastroretentive dosage forms for minocycline
EP2817009A1 (en) * 2012-02-23 2014-12-31 INSERM - Institut National de la Santé et de la Recherche Médicale Calcineurin inhibitors for use in the treatment of lesional vestibular disorders
BR112014024159A2 (pt) * 2012-03-29 2017-06-20 Therabiome Llc Formulações de vacina oral específicas do local gastrintestinal , ativas no íleo e apêndice.
JP2015515982A (ja) * 2012-05-04 2015-06-04 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 経口メチルナルトレキソンのバイオアベイラビリティはホスファチジルコリンベースの製剤で増加する
DE102012105528A1 (de) * 2012-06-25 2014-01-02 Hennig Arzneimittel Gmbh & Co. Kg Arzneiform zur Freisetzung von Wirkstoffen
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
JP5992247B2 (ja) * 2012-08-13 2016-09-14 国立大学法人大阪大学 核酸医薬経口製剤
JP6062802B2 (ja) * 2012-08-23 2017-01-18 日清ファルマ株式会社 キトサン含有組成物及びキトサンコーティング組成物
GB201304662D0 (en) 2013-03-14 2013-05-01 Sigmoid Pharma Ltd Compositions
WO2014152338A1 (en) 2013-03-14 2014-09-25 Kabadi Mohan Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
SG11201507140PA (en) * 2013-03-15 2015-10-29 Galleon Pharmaceuticals Inc Novel breathing control modulating compounds, and methods of using same
US10434088B2 (en) 2013-05-03 2019-10-08 Selecta Biosciences, Inc. Methods related to administering immunosuppressants and therapeutic macromolecules at a reduced pharmacodynamically effective dose
US9415110B1 (en) 2013-05-08 2016-08-16 The Arizona Board of Regents on behalf of the Univeristy of Arizona Method and compositions for targeted drug delivery to the lower GI tract
CN104127466B (zh) * 2013-08-23 2018-05-22 江苏省中医药研究院 一种淫羊藿总黄酮口服肠溶制剂及其应用
CN104548063A (zh) * 2013-10-29 2015-04-29 中国科学院上海有机化学研究所 一种免疫抑制剂在制备线粒体丝氨酸/苏氨酸蛋白磷酸酶抑制剂中的用途
GB201319792D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
HUP1300647A2 (hu) 2013-11-12 2015-05-28 Druggability Technologies Ip Holdco Jersey Ltd Ciklosporin A és származékainak komplexei, elõállításuk és gyógyszerészeti kompozícióik
EP3074028B1 (en) * 2013-11-27 2022-04-06 Research Foundation Of The City University Of New York Activity enhancing curcumin compositions and methods of use
GB201400442D0 (en) * 2014-01-10 2014-02-26 Sigmoid Pharma Ltd Compositions for use in the treatment of ulcerative colitis
JP2017521479A (ja) 2014-05-15 2017-08-03 ラニ セラピューティクス， エルエルシー ポリペプチドおよび／またはタンパク質を含む固体塊の薬学的組成物およびそれを製造するための方法
WO2016003536A1 (en) * 2014-06-30 2016-01-07 Salix Pharmaceuticals, Inc. Methods for retreating irritable bowel syndrome (ibs)
SG11201610250WA (en) 2014-07-01 2017-01-27 Probi Usa Inc Bi-layer dual release probiotic tablets
JP6665159B2 (ja) * 2014-08-04 2020-03-13 デベヴェ テクノロジーズＤｂｖ Ｔｅｃｈｎｏｌｏｇｉｅｓ 食物アレルゲン組成物
CN114794444A (zh) 2014-09-02 2022-07-29 谱赛科美国股份有限公司 富含莱鲍迪苷d、e、n和/或o的甜菊提取物及其制备方法
WO2016037165A1 (en) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Methods and compositions for attenuating exon skipping anti-viral transfer vector immune responses
CN104224732B (zh) * 2014-09-29 2017-06-30 江苏大学 一种口服骨架型环孢素a缓释微丸制剂及其制备方法
CA2902911C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
WO2016071515A1 (en) 2014-11-07 2016-05-12 Sigmoid Pharma Limited Compositions comprising cyclosporin
EP3236993B1 (en) 2014-12-23 2023-09-13 Theriva Biologics, Inc. Methods and compositions for inhibiting or preventing adverse effects of oral antibiotics
CN104473907A (zh) * 2014-12-25 2015-04-01 北京华禧联合科技发展有限公司 一种他克莫司的口服缓释制剂
WO2016128970A1 (en) 2015-02-09 2016-08-18 Entera Bio Ltd. Treatment of hypoparathyroidism
CN107427577A (zh) 2015-03-31 2017-12-01 韦斯夸尔德有限公司 具有蛋白酶可切割接头的肽构建体
WO2016156468A1 (en) 2015-03-31 2016-10-06 Vhsquared Limited Polypeptides
AU2016257813B2 (en) 2015-05-01 2021-05-13 Rani Therapeutics, Llc Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins
US10286009B2 (en) * 2015-05-16 2019-05-14 Asterias Biotherapeutics, Inc. Pluripotent stem cell-derived oligodendrocyte progenitor cells for the treatment of spinal cord injury
EP3302442B1 (en) 2015-06-03 2024-10-16 Triastek, Inc. Dosage forms and use thereof
JP7224917B2 (ja) * 2016-03-31 2023-02-20 ソリッソ ファーマシューティカルズ，インク． 組成物
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
TR201610597A2 (tr) * 2016-07-29 2016-12-21 Kamil Varlik Erel Mide ve bağırsak içine yerleştirilen tüp veya sondalardan kullanıma uygun ilaç
EP3500291A4 (en) * 2016-08-17 2020-03-11 Entera Bio Ltd. FORMULA FOR ORAL ADMINISTRATION OF ACTIVE SUBSTANCES
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
WO2018112264A1 (en) * 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
MX2019006823A (es) * 2016-12-14 2019-10-21 Progenity Inc Tratamiento de una enfermedad del tracto gastrointestinal con inhibidor de interleucina-12/interleucina-23 (il-12/il-23) liberado usando un dispositivo ingerible.
US11523772B2 (en) 2016-12-14 2022-12-13 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immunosuppressant
WO2018112215A1 (en) * 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
WO2018137686A1 (en) * 2017-01-26 2018-08-02 Triastek, Inc. Dosage forms of controlled release at specific gastrointestinal sites
CA3055936A1 (en) 2017-03-11 2018-09-20 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
WO2018183931A1 (en) * 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist
US20200094031A1 (en) * 2017-03-30 2020-03-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor
EP3600416B1 (en) * 2017-03-30 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
CA3064891A1 (en) * 2017-06-14 2018-12-20 SpecGx LLC Delayed sustained release pharmaceutical compositions
US11865145B2 (en) 2017-08-07 2024-01-09 Finch Therapeutics Holdings Llc Compositions and methods for maintaining and restoring a healthy gut barrier
CN111225686A (zh) * 2017-08-15 2020-06-02 普罗根尼蒂公司 使用可摄入装置释放免疫调节剂治疗炎性疾病
EP3459527B1 (en) 2017-09-20 2022-11-23 Tillotts Pharma Ag Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization
EP3672608A4 (en) * 2017-10-05 2021-09-01 Receptor Holdings, Inc. HERBAL COMPOSITION WITH IMPROVED BIOAVAILABILITY
CA3075292A1 (en) * 2017-10-20 2019-04-25 Purdue Pharma L.P. Pharmaceutical dosage forms
EP3723801B9 (en) * 2017-12-14 2023-10-04 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a s1p modulator
US11338020B2 (en) 2018-01-09 2022-05-24 Synthetic Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
CN108379238B (zh) * 2018-01-17 2020-07-14 南昌大学 一种储存物理稳定性好的环孢素固体脂质纳米粒及其制备方法
AU2019224114A1 (en) 2018-02-23 2020-09-10 Finch Therapeutics Holdings Llc Microbiome related immunotherapies
CN112074197A (zh) * 2018-03-07 2020-12-11 安纳生物科技有限公司 用于ii型糖尿病及用于提供随着时间的持续的能量释放的组合物
US10835489B2 (en) 2018-03-09 2020-11-17 University Of Saskatchewan Modified release formulations of mycophenolate mofetil
JP2021518444A (ja) * 2018-03-19 2021-08-02 ジェミニ ラボラトリーズ エルエルシー 免疫抑制剤の剤形と使用方法
US11638699B2 (en) 2018-03-20 2023-05-02 Theriva Biologics, Inc. Intestinal alkaline phosphatase formulations
EP4275761A3 (en) 2018-03-20 2024-02-28 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
WO2020106330A1 (en) * 2018-07-18 2020-05-28 Pillsy, Inc. Smart drug delivery and monitoring device, kit, and method of use for pill compounds
CA3110250A1 (en) 2018-08-22 2020-02-27 Bacainn Therapeutics, Ltd. Cyclosporine compositions and methods of use
CN113646422B (zh) 2018-09-19 2025-03-11 谱系细胞疗法股份有限公司 用于在动态悬浮培养中分化多能干细胞的方法
CN110934831B (zh) * 2018-09-25 2021-09-14 天津大学 二甲基乙二酰甘氨酸-白藜芦醇核壳型纳米材料及其制备方法
CA3113948A1 (en) * 2018-10-11 2020-04-16 Alivio Therapeutics, Inc. Non-injectable hydrogel formulations for smart release
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
MX2021005807A (es) 2018-11-19 2021-07-02 Receptor Holdings Inc Aminoacidos grasos n-acilados para reducir la variabilidad de absorcion en composiciones basadas en cannabinoides.
CA3187170A1 (en) 2019-03-13 2020-09-17 University Of Virginia Patent Foundation Compositions and methods for promoting islet viability and enhancing insulin secretion
US10752642B1 (en) 2019-04-30 2020-08-25 George Mason University Macrocyclic lactones
AU2020296979A1 (en) 2019-06-21 2022-02-24 Sorriso Pharmaceuticals, Inc. Polypeptides
CN114466864B (zh) 2019-06-21 2024-12-27 索瑞索制药公司 多肽
WO2021011754A1 (en) 2019-07-18 2021-01-21 Synthetic Biologics, Inc. Intestinal alkaline phosphatase-based treatments of metabolic disorders
JP2022541795A (ja) 2019-07-19 2022-09-27 フィンチ セラピューティクス ホールディングス エルエルシー 胃腸障害の治療のための方法および産物
CA3148226A1 (en) 2019-08-12 2021-02-18 Massachusetts Institute Of Technology Articles and methods for administration of therapeutic agents
BR112022002962A2 (pt) 2019-08-16 2022-07-05 Applied Molecular Transport Inc Composições, formulações e produção e purificação de interleucina
WO2021050965A1 (en) 2019-09-13 2021-03-18 Crestovo Holdings Llc Compositions and methods for treating autism spectrum disorder
EP4045630A1 (en) 2019-10-18 2022-08-24 Finch Therapeutics Holdings LLC Compositions and methods for delivering a bacterial metabolite to a subject
WO2021097288A1 (en) 2019-11-15 2021-05-20 Finch Therapeutics Holdings Llc Compositions and methods for treating neurodegenerative diseases
CN111297953A (zh) * 2019-12-20 2020-06-19 卓和药业集团有限公司 一种预防肾脏移植后移植排斥反应的复方制剂
TW202140049A (zh) 2020-01-10 2021-11-01 美商芬奇治療控股有限責任公司 用於治療ｂ型肝炎（ｈｂｖ）及ｄ型肝炎（ｈｄｖ）之組合物及方法
WO2021142347A1 (en) 2020-01-10 2021-07-15 Finch Therapeutics Holdings Llc Compositions and methods for non-alcoholic steatohepatitis (nash)
WO2021142358A1 (en) 2020-01-10 2021-07-15 Finch Therapeutics Holdings Llc Compositions and methods for treating hepatic encephalopathy (he)
US20230149295A1 (en) * 2020-03-09 2023-05-18 University Of Houston System Inflammatory bowel disease stem cells, agents which target ibd stem cells, and uses related thereto
WO2021202806A1 (en) 2020-03-31 2021-10-07 Finch Therapeutics Holdings Llc Compositions comprising non-viable fecal microbiota and methods of use thereof
GB202006390D0 (en) * 2020-04-30 2020-06-17 Aqilion Ab Novel treatments
US11426353B2 (en) * 2020-06-24 2022-08-30 13400719 Canada Inc. Composite coating for an active agent
US11666560B2 (en) 2020-09-24 2023-06-06 George Mason University Anti-fibrotic agent
WO2022103798A1 (en) * 2020-11-10 2022-05-19 Medregen, Llc Formulations, methods, kits, and dosage forms
EP4251134A4 (en) * 2020-11-30 2024-05-29 Royal Melbourne Institute of Technology ORAL THERAPEUTIC ADMINISTRATION
US20240263251A1 (en) 2021-02-19 2024-08-08 Finch Therapeutics Holdings Llc Compositions and methods for providing secondary bile acids to a subject
ES2924573B2 (es) * 2021-03-18 2024-04-24 Aora Health S L Sistema de administracion en multiples sitios para administracion diferencial en el tracto gastrointestinal
WO2023043854A1 (en) * 2021-09-14 2023-03-23 Nulixir Inc. Alimentary-related particles, production methods, and production apparatus
KR102874663B1 (ko) * 2021-12-22 2025-10-23 알고케어 주식회사 구 형상의 제형을 제공하는 디스펜서
CN114916591A (zh) * 2022-06-09 2022-08-19 江西维尔宝食品生物有限公司 一种起酥性烘焙专用可塑性粉末油脂组合物
US11806430B1 (en) 2023-02-24 2023-11-07 King Faisal University Rectal gel with date palm phenolics and vanillic acid
AU2024252387A1 (en) * 2023-04-14 2025-10-02 Vitakey Inc. Compositions and methods of controlling mammalian satiety
CN116650444B (zh) * 2023-07-31 2023-10-31 国药集团川抗制药有限公司 一种他克莫司缓释药物及其制备方法
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (217)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US3971852A (en) 1973-06-12 1976-07-27 Polak's Frutal Works, Inc. Process of encapsulating an oil and product produced thereby
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IT1090703B (it) 1976-12-03 1985-06-26 Scherer Ltd R P Perfezionamento nelle composizioni utili quali veicolo per farmaci
SE445174B (sv) 1978-03-07 1986-06-09 Sandoz Ag Farmaceutisk komposition innehallande en cyklosporin och en berarsubstans
US4279632A (en) 1979-05-08 1981-07-21 Nasa Method and apparatus for producing concentric hollow spheres
IT1148784B (it) 1980-04-09 1986-12-03 Eurand Spa Procedimento per la preparazione di microcapsule in un veicolo liquido
US4379454A (en) * 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
JPS6415Y2 (cg-RX-API-DMAC7.html) 1981-05-29 1989-01-05
JPS5877810A (ja) 1981-11-01 1983-05-11 Taiho Yakuhin Kogyo Kk ポリグリセロ−ル不飽和脂肪酸エステルを含む経口薬剤組成物
DE3224619A1 (de) * 1981-07-14 1983-05-19 Freund Industrial Co., Ltd., Tokyo Orale pharmazeutische zusammensetzung
JPS5813508A (ja) 1981-07-14 1983-01-26 Taiho Yakuhin Kogyo Kk ポリグリセロール飽和脂肪酸エステルを含む経口薬剤組成物
US4481157A (en) 1982-04-27 1984-11-06 Morishita Jintan Co., Ltd. Method and apparatus for production of microcapsules
US4597959A (en) 1982-04-30 1986-07-01 Arthur Barr Sustained release breath freshener, mouth and palate coolant wafer composition and method of use
US4422985A (en) 1982-09-24 1983-12-27 Morishita Jintan Co., Ltd. Method and apparatus for encapsulation of a liquid or meltable solid material
JPS5988420A (ja) 1982-11-12 1984-05-22 Teisan Seiyaku Kk シ−ムレスカプセル化ニフエジピン製剤
JPS5988420U (ja) 1982-12-04 1984-06-15 有限会社三和ボタン店 学生服の詰襟構造
JPS59131355A (ja) * 1983-01-17 1984-07-28 森下仁丹株式会社 多重軟カプセルの製法
HU187215B (en) * 1983-01-26 1985-11-28 Egyt Gyogyszervegyeszeti Gyar Method for producing pharmaceutical product of high actor content and prolonged effect
DE3331009A1 (de) 1983-08-27 1985-03-14 Basf Ag, 6700 Ludwigshafen Verfahren zur erhoehung der enteralen resorbierbarkeit von heparin bzw. heparinoiden sowie das so erhaeltliche heparin- bzw. heparinoidpraeparat
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
JPS6115A (ja) 1984-06-12 1986-01-06 Kyowa Hakko Kogyo Co Ltd リポキシゲナ−ゼ代謝産物に起因する疾患の予防治療剤
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
JPS61115462A (ja) 1984-11-13 1986-06-03 Denka Seiyaku Kk 甘味増強ステビア葉の製法
JPS61151119A (ja) 1984-12-24 1986-07-09 Taisho Pharmaceut Co Ltd ソフトカプセル
US4601894A (en) * 1985-03-29 1986-07-22 Schering Corporation Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate
US4658441A (en) * 1985-12-13 1987-04-21 Smith Steven A One piece thumb support and protector
US4749574A (en) 1986-04-14 1988-06-07 Fujisawa Pharmaceutical Co., Ltd. Sustained-release transdermal delivery preparations
US4857335A (en) 1987-03-27 1989-08-15 Lim Technology Laboratories, Inc. Liquid controlled release formulations and method of producing same via multiple emulsion process
ATE109970T1 (de) * 1987-09-03 1994-09-15 Univ Georgia Res Found Cyclosporin-augenmittel.
US4891223A (en) 1987-09-03 1990-01-02 Air Products And Chemicals, Inc. Controlled release delivery coating formulation for bioactive substances
JPS6415A (en) 1988-03-17 1989-01-05 Freunt Ind Co Ltd Absorption-improving drug preparation
US4910191A (en) * 1988-06-28 1990-03-20 Merrell Dow Pharmaceuticals Inc. 19-substituted progesterone derivatives useful as 19-hydroxylase inhibitors
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5350741A (en) 1988-07-30 1994-09-27 Kanji Takada Enteric formulations of physiologically active peptides and proteins
US5342625A (en) 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
KR0148748B1 (ko) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
WO1990006775A1 (en) 1988-12-14 1990-06-28 Liposome Technology, Inc. A novel nonphospholipid liposome composition for sustained release of drugs
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
JP2806564B2 (ja) 1989-07-20 1998-09-30 森下仁丹株式会社 親水性物質を内容物とするシームレスカプセルおよびその製法
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
GB8926639D0 (en) 1989-11-24 1990-01-17 Agricultural & Food Res Delayed release formulations
US5260071A (en) * 1989-12-18 1993-11-09 Lemelson Jerome H Drug units and methods for using same
BE1003677A3 (nl) 1990-01-29 1992-05-19 Schacht Etienne Werkwijze voor het bereiden van azobevattende polymeren en het gebruik ervan als geneesmiddelafgiftesystemen.
IL98087A (en) 1990-05-04 1996-11-14 Perio Prod Ltd Preparation for dispensing drugs in the colon
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
ES2055541T3 (es) * 1990-07-04 1994-08-16 Shionogi & Co Un proceso para la preparacion de una capa de revestimiento no cohesiva.
US5102668A (en) 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
US5418010A (en) 1990-10-05 1995-05-23 Griffith Laboratories Worldwide, Inc. Microencapsulation process
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
GB9113872D0 (en) 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
EP0546158B1 (en) 1991-06-28 1998-01-07 Brown University Research Foundation Capsule extrusion systems
JP3313124B2 (ja) 1991-07-31 2002-08-12 森下仁丹株式会社 親水性物質を内容物とするシームレスカプセルおよびその製法
JPH0549899A (ja) 1991-08-09 1993-03-02 Japan Tobacco Inc ビーズ及びこれを製造するための液滴生成装置
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
AU666895B2 (en) 1991-12-30 1996-02-29 Hercules Incorporated High load spray dry encapsulation
DE4201179A1 (de) 1992-01-17 1993-07-22 Alfatec Pharma Gmbh Wirkstoff(e) enthaltendes granulat oder pellet mit einem geruest aus hydrophilen makromolekuelen und verfahren zu seiner herstellung
DE59307073D1 (de) 1992-01-17 1997-09-11 Alfatec Pharma Gmbh Peptidarzneistoffe enthaltende pellets und ihre herstellung sowie deren verwendung
US5571533A (en) 1992-02-07 1996-11-05 Recordati, S.A., Chemical And Pharmaceutical Company Controlled-release mucoadhesive pharmaceutical composition for the oral administration of furosemide
EP0573978B1 (en) 1992-06-12 1999-04-21 Kao Corporation Bath additive composition comprising surfactant-containing seamless capsules and method for producing the capsules.
JP3405746B2 (ja) * 1992-10-28 2003-05-12 フロイント産業株式会社 シームレスカプセルの製造方法
ATE218884T1 (de) 1993-01-08 2002-06-15 Csl Ltd Impfstoffpräparate
GB9300875D0 (en) 1993-01-18 1993-03-10 Ucb Sa Nanocapsule containing pharmaceutical compositions
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5686105A (en) * 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5914132A (en) 1993-02-26 1999-06-22 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5843347A (en) * 1993-03-23 1998-12-01 Laboratoire L. Lafon Extrusion and freeze-drying method for preparing particles containing an active ingredient
DK66493D0 (da) 1993-06-08 1993-06-08 Ferring A S Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling
CN1077800C (zh) * 1993-07-01 2002-01-16 韩美药品工业株式会社 环孢菌素软胶囊组合物
FR2707184B1 (fr) * 1993-07-08 1995-08-11 Rhone Poulenc Nutrition Animal Procédé de préparation de sphérules contenant un principe actif alimentaire ou pharmaceutique.
US6204243B1 (en) * 1993-09-01 2001-03-20 Novatis Ag Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis
DE4329503A1 (de) 1993-09-01 1995-03-02 Galenik Labor Freiburg Gmbh Pharmazeutische Präparate zur gezielten Behandlung von Morbus Crohn und Colitis Ulcerosa
DE4332041C2 (de) 1993-09-21 1997-12-11 Rentschler Arzneimittel Verwendung von Pentoxifyllin bei bestimmten Lungenerkrankungen
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
WO1995022343A1 (en) 1994-02-17 1995-08-24 Shiseido Company, Ltd. Cyclosporin-containing emulsion composition
US5498439A (en) 1994-03-04 1996-03-12 Arnhem, Inc. Process for encapsulating the flavor with colloid gel matrix
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
AU689250B2 (en) 1994-04-22 1998-03-26 Astellas Pharma Inc. Colon-specific drug release system
GB9412394D0 (en) 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
FR2721510B1 (fr) * 1994-06-22 1996-07-26 Rhone Poulenc Rorer Sa Nanoparticules filtrables dans des conditions stériles.
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
DE4430127A1 (de) * 1994-08-25 1996-03-14 Hoechst Ag Kombinationspräparat, enthaltend Cyclosporin A oder FK506 und ein Xanthinderivat
US5650232A (en) * 1994-10-07 1997-07-22 Warner-Lambert Company Method for making seamless capsules
FR2725623A1 (fr) * 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
US5827531A (en) 1994-12-02 1998-10-27 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Microcapsules and methods for making
US5529783A (en) * 1994-12-19 1996-06-25 Mcneil-Ppc, Inc. Rotor granulation and coating of acetaminophen, pseudoephedrine, chlorpheniramine, and, optionally dextromethorphan
KR0167613B1 (ko) 1994-12-28 1999-01-15 한스 루돌프 하우스, 니콜 케르커 사이클로스포린-함유 연질캅셀제 조성물
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5674495A (en) 1995-02-27 1997-10-07 Purdue Research Foundation Alginate-based vaccine compositions
US5595757A (en) 1995-03-29 1997-01-21 Warner-Lambert Company Seamless capsules
US5767153A (en) 1995-06-07 1998-06-16 Insite Vision Incorporated Sustained release emulsions
US5716928A (en) 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5665386A (en) 1995-06-07 1997-09-09 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
IE80467B1 (en) 1995-07-03 1998-07-29 Elan Corp Plc Controlled release formulations for poorly soluble drugs
SE504582C2 (sv) 1995-07-06 1997-03-10 Gs Dev Ab Cyklosporinkomposition baserad på en L2-fas
JP2682818B2 (ja) 1995-08-04 1997-11-26 大成化工株式会社 害虫誘引阻止材
IL120673A0 (en) * 1995-08-25 1997-08-14 Sangstat Medical Corp Oral cyclosporin formulations
EP0760237A1 (en) * 1995-08-30 1997-03-05 Cipla Limited Oil-in-water microemulsions
DE19549852B4 (de) * 1995-11-29 2009-06-04 Novartis Ag Cyclosporin enthaltende Präparate
JP3759986B2 (ja) * 1995-12-07 2006-03-29 フロイント産業株式会社 シームレスカプセルおよびその製造方法
KR19990077278A (ko) 1996-01-16 1999-10-25 마이클 오코넬 약물의 하부 위장관으로의 국소적 전달
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US5686133A (en) 1996-01-31 1997-11-11 Port Systems, L.L.C. Water soluble pharmaceutical coating and method for producing coated pharmaceuticals
US5889028A (en) * 1996-02-09 1999-03-30 Mayo Foundation For Medical Education And Research Colonic delivery of nicotine to treat inflammatory bowel disease
KR0183449B1 (ko) * 1996-06-19 1999-05-01 한스 루돌프 하우스, 니콜 케르커 사이클로스포린-함유 연질캅셀제
US5958876A (en) 1996-06-19 1999-09-28 Novartis Ag Cyclosporin-containing pharmaceutical compositions
CA2269806C (en) 1996-10-28 2006-01-24 Bernhard H. Van Lengerich Embedding and encapsulation of controlled release particles
US5891474A (en) * 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
JP2001515491A (ja) 1997-03-12 2001-09-18 アボツト・ラボラトリーズ 親油性化合物の投与のための親油性二成分系
DZ2479A1 (fr) * 1997-05-05 2003-02-01 Pfizer Composés inhibiteurs sélectifs de cox-2 anti-inflammatoires et compositions pharmaceutiques les contenant.
WO1998050018A1 (en) 1997-05-06 1998-11-12 Xiao Yu Wu Drug delivery system
JP4102459B2 (ja) 1997-05-14 2008-06-18 森下仁丹株式会社 生体高分子を合成するシームレスカプセルおよびその製造方法
SE9702533D0 (sv) 1997-07-01 1997-07-01 Astra Ab New oral formulation
WO1999006024A1 (en) 1997-07-29 1999-02-11 Pharmacia & Upjohn Company Self-emulsifying formulation for lipophilic compounds
DE19732903A1 (de) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
ES2137862B1 (es) 1997-07-31 2000-09-16 Intexim S A Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
JP3090198B2 (ja) * 1997-08-21 2000-09-18 日本電気株式会社 半導体装置の構造およびその製造方法
HUP9701554D0 (en) * 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
US6531150B1 (en) * 1997-10-30 2003-03-11 Morishita Jintan Co., Ltd. Encapsulated unsaturated fatty acid substance and method for producing the same
US5891845A (en) 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
IT1296585B1 (it) 1997-11-28 1999-07-14 Uni Di Pavia Microcapsule contenenti materiale seminale per l'inseminazione strumentale nella specie suina
US6509346B2 (en) * 1998-01-21 2003-01-21 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US20040062802A1 (en) 1998-04-02 2004-04-01 Hermelin Victor M. Maximizing effectiveness of substances used to improve health and well being
US6174466B1 (en) * 1998-05-08 2001-01-16 Warner-Lambert Company Methods for making seamless capsules
DE19821951A1 (de) * 1998-05-15 1999-11-18 Basf Ag Cyclosporin-Zubereitungen
JPH11322587A (ja) 1998-05-18 1999-11-24 Sumitomo Chem Co Ltd 常温で固体の生理活性物質のマイクロカプセル化方法およびこの方法により得られるマイクロカプセル組成物
KR100336090B1 (ko) 1998-06-27 2002-05-27 윤승원 오일, 지방산 또는 이들의 혼합물을 함유한 난용성 약물의 고형분산제제
ES2234306T3 (es) 1998-09-28 2005-06-16 Warner-Lambert Company Llc Administracion enterica y via colon usando capsulas de hpmc.
DE19848849A1 (de) 1998-10-22 2000-04-27 Knoll Ag Verfahren zur Herstellung von festen, sphärischen Formen, enthaltend eine biologisch aktive Substanz
JP2002531515A (ja) 1998-12-11 2002-09-24 ファーマソリューションズ・インコーポレイテッド 水に難溶性の薬剤のための自己乳化組成物
JP3039863B1 (ja) 1998-12-25 2000-05-08 不二精工株式会社 ロッキングプレス装置
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
JP2000247911A (ja) 1999-02-26 2000-09-12 Hisamitsu Pharmaceut Co Inc 大腸用吸収促進剤
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20030104048A1 (en) 1999-02-26 2003-06-05 Lipocine, Inc. Pharmaceutical dosage forms for highly hydrophilic materials
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
JP2000302654A (ja) 1999-04-16 2000-10-31 Kao Corp 歯磨組成物の製造法
KR20020011985A (ko) 1999-05-07 2002-02-09 파르마솔 게엠베하 액상 및 고체상 지질 혼합물에 기초한 지질입자들 및 그의제조방법
WO2000069420A1 (en) 1999-05-14 2000-11-23 Coraltis Ltd. Pulse-delivery oral compositions
WO2000074720A1 (fr) * 1999-06-09 2000-12-14 Mochida Pharmaceutical Co., Ltd. Systeme de liberation dans les voies digestives inferieures
US20030235595A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Oil-containing, orally administrable pharmaceutical composition for improved delivery of a therapeutic agent
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6458383B2 (en) 1999-08-17 2002-10-01 Lipocine, Inc. Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
US20030236236A1 (en) 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
KR100710118B1 (ko) 1999-07-30 2007-04-23 스미스클라인비이참피이엘시이 다성분 제약학적 제형
AU1043201A (en) 1999-11-02 2001-05-14 Cipla Limited Cyclosporin formulation
US20030180352A1 (en) 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20060034937A1 (en) 1999-11-23 2006-02-16 Mahesh Patel Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
JP2004504264A (ja) * 2000-01-07 2004-02-12 ユニバーシティ　オブ　シンシナティ Ｔｈ１又はｔｈ２リンパ球に制御される免疫応答の選択的活性化
CA2407154A1 (en) 2000-04-27 2001-11-01 Verion, Inc Zero order release and temperature-controlled microcapsules and process for the preparation thereof
WO2001087270A2 (en) 2000-05-12 2001-11-22 Pharmacia & Upjohn Company Vaccine composition, method of preparing the same, and method of vaccinating vertebrates
GB0018527D0 (en) 2000-07-27 2000-09-13 Photocure Asa Composition
FI20002215A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
CA2359812C (en) 2000-11-20 2004-02-10 The Procter & Gamble Company Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures
CA2441007C (en) 2001-03-15 2009-06-09 Enteron Pharmaceuticals, Inc. Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids
US6585997B2 (en) 2001-08-16 2003-07-01 Access Pharmaceuticals, Inc. Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
US20030083286A1 (en) 2001-08-22 2003-05-01 Ching-Leou Teng Bioadhesive compositions and methods for enhanced intestinal drug absorption
US6669955B2 (en) 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
FR2830447B1 (fr) 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US6951655B2 (en) 2001-10-11 2005-10-04 Imi Biomed, Inc. Pro-micelle pharmaceutical compositions
US20040126428A1 (en) * 2001-11-02 2004-07-01 Lyn Hughes Pharmaceutical formulation including a resinate and an aversive agent
CA2471241A1 (en) 2001-12-20 2003-07-03 Bernard Charles Sherman Pharmaceutical compositions comprising a cyclosporin, a hydrophilic surfactant and a lipophilic surfactant
EP1465502B1 (en) 2002-01-10 2006-07-26 Firmenich Sa Process for the preparation of extruded delivery systems
GB0203421D0 (en) * 2002-02-13 2002-04-03 Alizyme Therapeutics Ltd Composition
US6974592B2 (en) 2002-04-11 2005-12-13 Ocean Nutrition Canada Limited Encapsulated agglomeration of microcapsules and method for the preparation thereof
US20030207907A1 (en) 2002-05-03 2003-11-06 Iversen Patrick L. Delivery of microparticle-conjugated drugs for inhibition of stenosis
JP4226846B2 (ja) * 2002-06-07 2009-02-18 キャタレント・ジャパン株式会社 口腔内で崩壊可能なソフトカプセル剤
GB2391473B (en) 2002-08-02 2004-07-07 Satishchandra Punambhai Patel Pharmaceutical compositions
AU2003265481A1 (en) 2002-09-04 2004-03-29 Southwest Research Institute Microencapsulation of oxygen or water sensitive materials
KR20050083855A (ko) 2002-11-01 2005-08-26 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 ＨＩＦ-1 알파의 ｓｉＲＮＡ 억제를 위한 조성물 및 방법
US7670627B2 (en) 2002-12-09 2010-03-02 Salvona Ip Llc pH triggered targeted controlled release systems for the delivery of pharmaceutical active ingredients
US7524515B2 (en) 2003-01-10 2009-04-28 Mutual Pharmaceuticals, Inc. Pharmaceutical safety dosage forms
WO2004064997A1 (en) 2003-01-23 2004-08-05 Inotech Ag New microcapsules useful as extraction means in particular for extracting water or soil contaminants
US20060167435A1 (en) * 2003-02-18 2006-07-27 Adamis Anthony P Transscleral drug delivery device and related methods
WO2004084870A1 (en) 2003-03-28 2004-10-07 Sigmoid Biotechnologies Limited Solid oral dosage form containing seamless microcapsules
BRPI0408635B1 (pt) 2003-04-04 2019-07-16 Zoetis Services Llc Método de preparação de uma emulsão de óleo em água microfluidizada na faixa dos submicrômetros com um tamanho médio de gotícula de óleo inferior a 0,5 ?m, emulsão de óleo em água microfluidizada, método de preparação de uma composição de vacina microfluidizada e composições de vacina microfluidizadas
US8614204B2 (en) * 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
EP1663217B1 (en) 2003-08-29 2010-07-07 LifeCycle Pharma A/S Solid dispersions comprising tacrolimus
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US20050095288A1 (en) * 2003-11-03 2005-05-05 Andrx Labs, Llc Decongestant and expectorant tablets
CN1893930B (zh) * 2003-11-21 2012-06-27 联邦科学和工业研究组织 胃肠道递送系统
CA2548992A1 (en) 2003-12-11 2005-08-11 Vaxdesign Corporation Immunotherapy compositions, method of making and method of use thereof
CN1268325C (zh) 2004-01-18 2006-08-09 浙江大学 三重复合微球制剂及其制备方法
AU2005210668A1 (en) 2004-01-30 2005-08-18 Angiotech International Ag Compositions and methods for treating contracture
AR048033A1 (es) 2004-03-12 2006-03-22 Smithkline Beecham Plc Composicion farmaceutica para moldear componentes que comprende copolimero de poli(met)acrilato, cubierta, conector o espaciador de capsula moldeado por inyeccion que tiene la composicion farmaceutica y forma de dosificacion farmaceutica de multicomponentes a partir de dicha composicion
FR2867395B1 (fr) 2004-03-15 2006-06-16 Rhodia Chimie Sa Emulsion sechee, son procede de preparation, et ses utilisations
EP1576881A1 (en) * 2004-03-15 2005-09-21 Urea Casale S.A. Process for the production of granules or pellets containing filamentary fungi
AU2005239838B2 (en) 2004-05-07 2011-08-11 Takeda Gmbh Pharmaceutical dosage form comprising pellets as well as its manufacturing process
GB0413730D0 (en) 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use
US20080124400A1 (en) 2004-06-24 2008-05-29 Angiotech International Ag Microparticles With High Loadings Of A Bioactive Agent
GB0417481D0 (en) * 2004-08-05 2004-09-08 Etiologics Ltd Combination therapy
WO2006026592A2 (en) 2004-08-27 2006-03-09 Spherics, Inc. Oral administration of poorly absorbed drugs, methods and compositions related thereto
US7718624B2 (en) * 2004-09-01 2010-05-18 Sitkovsky Michail V Modulation of immune response and inflammation by targeting hypoxia inducible factors
WO2006029018A2 (en) * 2004-09-02 2006-03-16 Bionaut Pharmaceuticals, Inc. Combinatorial chemotherapy treatment using na+/k+-atpase inhibitors
CA2581816A1 (en) * 2004-09-27 2006-04-06 Sigmoid Biotechnologies Limited Microcapsules comprising a methylxanthine and a corticosteroid
IE20050639A1 (en) * 2004-09-27 2006-09-06 Sigmoid Biotechnologies Ltd Minicapsule formulations
FI20041425A0 (fi) * 2004-11-05 2004-11-05 Orion Corp Transmukosaalinen veterinäärinen koostumus
WO2006104703A1 (en) * 2005-03-29 2006-10-05 Mcneil-Ppc, Inc. Compositions with hydrophilic drugs in a hydrophobic medium
EP1868582A4 (en) 2005-04-12 2011-06-22 Elan Pharma Int Ltd NANOTEILS AND CONTROLLED RELEASED COMPOSITIONS WITH CYCLOSPORIN
EP1906940A2 (en) 2005-07-26 2008-04-09 Glaxo Group Limited Encapsulation of lipid-based formulations in enteric polymers
CA2615939A1 (en) 2005-08-02 2007-02-08 Miv Therapeutics Inc. Microdevices comprising nanocapsules for controlled delivery of drugs and method of manufacturing same
US7842312B2 (en) 2005-12-29 2010-11-30 Cordis Corporation Polymeric compositions comprising therapeutic agents in crystalline phases, and methods of forming the same
US9265811B2 (en) 2006-02-09 2016-02-23 Alba Therapeutics Corporation Formulations for a tight junction effector
US20070274932A1 (en) * 2006-05-15 2007-11-29 The Procter & Gamble Company Water in oil emulsion compositions containing sunscreen actives and siloxane elastomers
US8039010B2 (en) * 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
US20080124279A1 (en) 2006-11-17 2008-05-29 Antoine Andremont Colonic delivery using Zn/pectin beads with a Eudragit coating
JP2010523555A (ja) * 2007-04-04 2010-07-15 シグモイド・ファーマ・リミテッド 「経口医薬組成物」
CA2685591A1 (en) 2007-05-01 2008-11-06 Sigmoid Pharma Limited Pharmaceutical nimodipine compositions
US9833510B2 (en) 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
US8962530B2 (en) 2007-06-27 2015-02-24 Regents Of The University Of Colorado Inflammatory bowel disease therapies
US20090143343A1 (en) 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract

Also Published As

Publication number Publication date
WO2008122967A2 (en) 2008-10-16
US8911777B2 (en) 2014-12-16
CN103120653B (zh) 2015-09-30
CN103316326A (zh) 2013-09-25
EP2066309A2 (en) 2009-06-10
EP2061440A2 (en) 2009-05-27
CA2683409A1 (en) 2008-10-16
CN101686948B (zh) 2013-06-19
CA2683415A1 (en) 2008-10-16
JP2016074686A (ja) 2016-05-12
US9114071B2 (en) 2015-08-25
US20100255087A1 (en) 2010-10-07
US20130330411A1 (en) 2013-12-12
CN103316326B (zh) 2016-06-15
JP2010523553A (ja) 2010-07-15
US9675558B2 (en) 2017-06-13
JP2017160241A (ja) 2017-09-14
EP2380564B1 (en) 2014-10-22
JP2010523555A (ja) 2010-07-15
JP5553747B2 (ja) 2014-07-16
CA2683407C (en) 2016-09-20
US20160166635A1 (en) 2016-06-16
US20150374638A1 (en) 2015-12-31
JP6059688B2 (ja) 2017-01-11
US20100297221A1 (en) 2010-11-25
US20200009218A1 (en) 2020-01-09
US20120258167A1 (en) 2012-10-11
US10434139B2 (en) 2019-10-08
US20200009219A1 (en) 2020-01-09
US10434140B2 (en) 2019-10-08
WO2008122967A3 (en) 2008-12-24
CN101677964A (zh) 2010-03-24
EP2380564A2 (en) 2011-10-26
DK2079456T3 (da) 2013-03-18
WO2008122965A3 (en) 2008-12-24
HRP20130173T1 (hr) 2013-04-30
CY1113882T1 (el) 2016-07-27
WO2008122965A2 (en) 2008-10-16
JP2014196368A (ja) 2014-10-16
CN105030729A (zh) 2015-11-11
EP2380564A3 (en) 2012-11-14
US9387179B2 (en) 2016-07-12
WO2008122966A3 (en) 2008-12-24
ES2393814T3 (es) 2012-12-28
US9585844B2 (en) 2017-03-07
CN103120653A (zh) 2013-05-29
US20170246242A1 (en) 2017-08-31
CN101686948A (zh) 2010-03-31
ES2400964T3 (es) 2013-04-15
CA2683407A1 (en) 2008-10-16
JP2010523554A (ja) 2010-07-15
CA2683415C (en) 2020-12-08
US20170196934A1 (en) 2017-07-13
CN101990429A (zh) 2011-03-23
EP2079456B1 (en) 2012-12-05
EP2079456A2 (en) 2009-07-22
EP2409691A1 (en) 2012-01-25
ES2524345T3 (es) 2014-12-05
US9844513B2 (en) 2017-12-19
JP6149090B2 (ja) 2017-06-14
EP2066309B1 (en) 2012-08-29
WO2008122966A2 (en) 2008-10-16
US8535713B2 (en) 2013-09-17
US20100203120A1 (en) 2010-08-12

Similar Documents

Publication Publication Date Title
PT2079456E (pt) Composições farmacêuticas de ciclosporina
IL283205A (en) Attached medicinal substance that binds to cells, preparations containing them and their uses
WO2007098128A3 (en) Phenylephrine-containing liquid formulations
IL233925A0 (en) Pharmaceutical dose for oral administration in the form of tiny particles to prevent incorrect use
IL208937A0 (en) Cell binding agent cytotoxic drug conjugates, compositions comprising the same and uses thereof
EP2143713A4 (en) NEW PYRROLINONE DERIVATIVE AND MEDICAL COMPOSITION CONTAINING THIS
EP2123274A4 (en) MEDICINAL COMPOSITION FOR TRANSDERMAL ABSORPTION, MEDICINAL COMPOSITION STORAGE UNIT, AND TRANSDERMAL ABSORPTION PREPARATION USING THE SAME
IL247741B (en) Pharmaceutical preparations containing iron oxo-hydroxide, methods for their preparation and their uses
IL203915A (en) Annotations of 2-Benzylphenyl-6-Hydroxymethyl-Tetrahydro-2 H-Pyrene-3,4,5-Triol
IL195488A (en) Compounds, pharmaceuticals containing them and their uses
IL196033A0 (en) Pyrrolotriazine derivatives and pharmaceutical compositions containing the same
IL185390A (en) A solid dosage form
IL234166B (en) Isoindoline compounds, a pharmaceutical composition containing it and its use in the preparation of a medicine
IL194460A0 (en) Deazapurine derivatives and pharmaceutical compositions containing the same
IL193240A0 (en) Dihydrodiazepine derivatives and pharmaceutical compositions containing the same
IL206395A (en) N- Heterocyclic-7-Oxo-6-Sulphoxy-6,1-Diazabicyclo [1.2.3] Octane-2-Carboxamides and Pharmaceuticals Containing Them
IL188494A0 (en) Novel 2,4-dianlinopyrimidine derivatives, the preparation thereof, their use as medicaments, pharmaceutical compositions and, in particular, as ikk inhibitors
IL183357A0 (en) Oral medicament for the modified release of at least one active principle, in multimicrocapsule form
IL179207A0 (en) Pyrrole derivatives and pharmaceutical compositions containing the same
ZA200608029B (en) Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs
IL193164A0 (en) Polymeric conjugates of 7-ethyl-10-hydroxycamptothecin and pharmaceutical compositions containing the same
EP2008643A4 (en) GEL COMPOSITION AND COSMETIC PRODUCT USING THE SAME
GB2452696B (en) 3-(2',2'-dimethylpropanoylamino)-tetrahydropyridin-2-one and its use in pharmaceutical compositions
EP1916251A4 (en) ERIANINE SALTS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
EP2351566A4 (en) PHARMACEUTICAL COMPOSITION WITH IMPROVED INFLUENCE ON THE DARMTRACT